Drug giants give up on Alzheimer's cure

Research too difficult and costly, say pharmaceutical companies

The world's leading pharmaceutical companies are downgrading the search for new treatments for Alzheimer's disease after the failure of a series of high-profile drugs trials.

The human and financial costs of the disease are growing rapidly as the population ages, but the prospects of treatments to halt it, or slow its progress, are receding as at least five trials in the past five years have delivered disappointing results.

This year, a trial of Dimebon, backed by Pfizer, the US pharmaceutical giant, and reported in January, failed to show any benefit, instead costing the company $750m in lost investment.

In July, bapineuzumab, developed by Irish drug-maker Elan in association with Pfizer and the US multinational Johnson & Johnson, also failed to show an impact on symptoms.

In August, another US group, Eli Lilly, reported the failure of solanezumab, its second Alzheimer's drug to disappoint in two years. In 2010, a trial of semagacestat not only failed to slow the disease but worsened symptoms.

The setbacks have damaged confidence among drug makers in the field of neuroscience – brain research – which was already shaky.

Pharmaceutical manufacturers worldwide are under pressure and have been cutting back in the recession, but neuroscience has been disproportionately hit, with AstraZeneca, Pfizer, Merck, Sanofi, Novartis and GlaxoSmithKline all downsizing their European departments. Speaking at a briefing organised by the Science Media Centre yesterday, Eric Karran, director of research at Alzheimer's Research UK, said: "Neuroscience is a very challenging area. All companies are shedding jobs but neuroscience has had the highest attrition rate.

"AstraZeneca had a very large neuroscience group with some 300 scientists. It is reducing that to a team of 40, who will act as a virtual team – not doing their own research but monitoring developments and forging links with other companies."

Asked if the pipeline of new Alzheimer's drugs could run dry, he said: "That has always got to be a risk. My sense is not that companies want to move away [from Alzheimer's research] but that their shareholders are getting restive. That's capitalism – there is nothing we can do about that. But there is a huge public need."

At least 12 times as much was spent on cancer research as dementia research, yet dementia cost the country twice as much as cancer, he said.

Craig Ritchie, a leading Alzheimer's researcher at Imperial College, who runs a clinic for patients with dementia in west London, said: "The companies are streamlining their neuroscience departments and one can understand why. But it is hugely disappointing because there is massive unmet need.

"There is a shift to symptomatic treatments instead of disease-modifying ones. There is a lot less energy in the system than there used to be. We need a success story – a catalyst – to make people feel there is something to work towards."

Alzheimer's affects an estimated 500,000 people in the UK (a further 300,000 have other forms of dementia) and tens of millions worldwide, with the numbers expected to triple by 2050. It causes amnesia, loss of language, mood changes, apathy, psychosis and aggression.

The latest trials are thought to have failed because the drugs were given to patients too late in the disease process to have an effect, or were unable to pick up subtle changes in cognition over a relatively short period.

Alzheimer's, which is marked by the build-up of sticky protein clumps – amyloid plaques – in the brain, is thought to take at least 15 years to develop and by the time symptoms appear, it is too late to reverse.

Existing drugs, such as donepezil (Aricept), have limited benefits.

News
people Emma Watson addresses celebrity nude photo leak
News
Katie Hopkins appearing on 'This Morning' after she purposefully put on 4 stone.
peopleKatie Hopkins breaks down in tears over weight gain challenge
News
Boris Johnson may be manoeuvring to succeed David Cameron
i100
News
peopleHis band Survivor was due to resume touring this month
PROMOTED VIDEO
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Life and Style
ebooksFrom the lifespan of a slug to the distance to the Sun: answers to 500 questions from readers
News
people'It can last and it's terrifying'
News
In this photo illustration a school student eats a hamburger as part of his lunch which was brought from a fast food shop near his school, on October 5, 2005 in London, England. The British government has announced plans to remove junk food from school lunches. From September 2006, food that is high in fat, sugar or salt will be banned from meals and removed from vending machines in schools across England. The move comes in response to a campaign by celebrity TV chef Jamie Oliver to improve school meals.
science
Arts and Entertainment
tv
Life and Style
fashionModel of the moment shoots for first time with catwalk veteran
Life and Style
fashionPart of 'best-selling' Demeter scent range
News
i100
Sport
Tom Cleverley
footballLoan move comes 17 hours after close of transfer window
Sport
Alexis Sanchez, Radamel Falcao, Diego Costa and Mario Balotelli
footballRadamel Falcao and Diego Costa head record £835m influx
Life and Style
fashionAngelina Jolie's wedding dressed revealed
News
i100
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Science Teacher Urgently required for October start

    £6720 - £33600 per annum: Randstad Education Nottingham: We are currently recr...

    ICT Teacher

    £120 - £130 per day: Randstad Education Group: We are looking for an outstandi...

    Art & Design Teacher

    £120 - £130 per day: Randstad Education Group: We are looking for an outstandi...

    Assistant Management Accountant -S/West London - £30k - £35k

    £30000 - £35000 per annum: Ashdown Group: We are working with an exciting orga...

    Day In a Page

    'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

    'I’ll tell you what I would not serve - lamb and potatoes'

    US ambassador hits out at stodgy British food
    Radio Times female powerlist: A 'revolution' in TV gender roles

    A 'revolution' in TV gender roles

    Inside the Radio Times female powerlist
    Endgame: James Frey's literary treasure hunt

    James Frey's literary treasure hunt

    Riddling trilogy could net you $3m
    Fitbit: Because the tingle feels so good

    Fitbit: Because the tingle feels so good

    What David Sedaris learnt about the world from his fitness tracker
    Saudis risk new Muslim division with proposal to move Mohamed’s tomb

    Saudis risk new Muslim division with proposal to move Mohamed’s tomb

    Second-holiest site in Islam attracts millions of pilgrims each year
    Alexander Fury: The designer names to look for at fashion week this season

    The big names to look for this fashion week

    This week, designers begin to show their spring 2015 collections in New York
    Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

    'I like Orwell's writing as much as the next talented mediocrity'

    Will Self takes aim at Orwell's rules for writing plain English
    Meet Afghanistan's middle-class paint-ballers

    Meet Afghanistan's middle-class paint-ballers

    Toy guns proving a popular diversion in a country flooded with the real thing
    Al Pacino wows Venice

    Al Pacino wows Venice

    Ham among the brilliance as actor premieres two films at festival
    Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

    Neil Lawson Baker interview

    ‘I’ve gained so much from art. It’s only right to give something back’.
    The other Mugabe who is lining up for the Zimbabwean presidency

    The other Mugabe who is lining up for the Zimbabwean presidency

    Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
    The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

    The model for a gadget launch

    Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
    Alice Roberts: She's done pretty well, for a boffin without a beard

    She's done pretty well, for a boffin without a beard

    Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
    Get well soon, Joan Rivers - an inspiration, whether she likes it or not

    Get well soon, Joan Rivers

    She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
    Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

    A fresh take on an old foe

    Doctor Who Into the Dalek more than compensated for last week's nonsensical offering